Medicare is using one of its biggest hammers to try to fix the dialysis system

Federal health officials are trying to fix problems in the system with a big policy experiment: changing how dialysis providers are paid. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      The latest STAT Report is a deep dive into health care’s big bet on blockchain. Check it out here. Medicare is using one of its biggest hammers to try to fix the dialysis system: how providers are paid By Isabella Cueto OSCAR DEL POZO/AFP VIA GETTY IMAGES As a medical treatment, dialysis is a stopgap measure that fails to fix a chronic problem. As an industry, dialysis has significant flaws, including a lag in home dialysis use. Critics argue dialysis clinics have for decades shirked a responsibility to help patients get on the kidney transplant waitlist and receive organs from living donors — the gold standard.  Now federal health officials are trying to fix those problems with a big policy experiment. Read More Sponsor content by novavax How is Novavax responding to new variants? Novavax uses nanoparticle technology, allowing for quick engineering of vaccine antigens to help control the impact of new variants. Learn more. More great reads from STAT this week Minimal compliance, or meaningful change? Epic faces a crossroads as new rules put pressure on health data sharing By Casey Ross and Mohana Ravindranath ‘This program’s really saved us’: As Canada offers safer opioids to curb overdoses, will U.S. follow? By Andrew Joseph Is the Covid-19 pandemic over? The answer is more art than science By Helen Branswell Advances in treating the sickest Covid patients have stalled. Why? By Jason Mast Surgeons often take a fifth of the lungs to remove a small tumor. There may be a better way By Angus Chen Coors, Mondelez, and other big food companies want to sell CBD-filled food and drinks. The FDA is staunchly opposed By Nicholas Florko Opinion: Termination is the safest course for some high-risk pregnancies. Dobbs decision threatens that care By Jammie Law, Michael Pillinger and Julie Nusbaum After early wins, CRISPR gene editing is about to get a lot harder By Jason Mast Saturday, September 24, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser